Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(158 produtos)
- Bcr-Abl(113 produtos)
- EGFR(598 produtos)
- FAK(72 produtos)
- FLT(90 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(182 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(90 produtos)
- Src(81 produtos)
- Syk(37 produtos)
- Trombina(53 produtos)
- VDA(2 produtos)
- VEGFR(250 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2040 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
VEGFR-2/DHFR-IN-2
VEGFR-2/DHFR-IN-2 inhibits VEGFR-2 & DHFR (IC50: 0.623 & 9.085 μM), toxic to C26, HepG2, MCF7 cells (IC50: 3.59-8.38 μM), promising for cancer study.Fórmula:C21H21NO4Cor e Forma:SolidPeso molecular:351.4FAK inhibitor 7
CAS:FAK inhibitor7, a potent FAK inhibitor, demonstrates an IC50 of 3.58 nM. This compound effectively inhibits downstream signaling cascades of FAK (such as Src and AKT), which leads to cell cycle arrest at the G0/G1 phase and induces cytotoxic autophagy in ovarian cancer cells. Additionally, FAK inhibitor7 has been shown to suppress tumor metastasis and growth in ovarian cancer mouse models.Fórmula:C32H37N7O3Cor e Forma:SolidPeso molecular:567.68M-COPA
CAS:M-COPA disrupts Golgi, blocks MET & Arf1 activation, and inhibits angiogenesis via VEGFR & NF-kB pathways.Fórmula:C25H34N2O2Cor e Forma:SolidPeso molecular:394.55VEGFR-2/DHFR-IN-1
Compound 8b inhibits VEGFR-2/DHFR, combats various bacteria, and fights cancer cells.Fórmula:C20H18ClNO4Cor e Forma:SolidPeso molecular:371.81VEGFR-2-IN-15
VEGFR-2-IN-15 (Compound 14b) is a potent inhibitor of VEGFR-2. VEGFR-2-IN-15 inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.Fórmula:C23H18ClN3O4SCor e Forma:SolidPeso molecular:467.92JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Cor e Forma:SolidSi306
CAS:Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Fórmula:C25H26BrClN6OSCor e Forma:SolidPeso molecular:573.94EGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Fórmula:C19H21N3O2SCor e Forma:SolidPeso molecular:355.45GNE-431
CAS:GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Fórmula:C30H32N10O2Cor e Forma:SolidPeso molecular:564.64FLT3-ITD-IN-3
CAS:FLT3-ITD-IN-3 (13v) is an orally active inhibitor of FLT3-ITD (internal tandem duplication of FLT3), which works by blocking FLT3 signaling. This inhibition leads to cell cycle arrest in the G0/G1 phase and induces apoptosis. The compound is currently employed in studies related to acute myeloid leukemia (AML).Fórmula:C27H21ClF2N6O5Cor e Forma:SolidPeso molecular:582.943JAK-IN-23
"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."Fórmula:C23H22Cl2N4OCor e Forma:SolidPeso molecular:441.35FGFR-IN-5
CAS:FGFR-IN-5 is a potent inhibitor of FGFR. FGFR-IN-5 has potential for research in cancer diseases.Fórmula:C25H22N6O3Cor e Forma:SolidPeso molecular:454.48EGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Fórmula:C25H24ClN7O2Cor e Forma:SolidPeso molecular:489.96VEGFR-2-IN-12
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.Fórmula:C22H24N6O3SCor e Forma:SolidPeso molecular:452.53EGFR-IN-45
<p>EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.</p>Fórmula:C28H23N7OCor e Forma:SolidPeso molecular:473.53WS-11
CAS:WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Fórmula:C26H22FN9O2Cor e Forma:SolidPeso molecular:511.51FLT3/TrKA-IN-1
FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.Fórmula:C28H30N4O2Cor e Forma:SolidPeso molecular:454.56CEE321
CAS:CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.Fórmula:C18H16ClN5OCor e Forma:SolidPeso molecular:353.806DDO-02267
CAS:<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>Fórmula:C18H12N2O7SCor e Forma:SolidPeso molecular:400.362EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Fórmula:C16H16N4O2SCor e Forma:SolidPeso molecular:328.39
